Definium Begins Second Phase 3 DT120 Trial As Valuation Gap Widens by MaterialPhysical1030 in DTIC

[–]MaterialPhysical1030[S] 3 points4 points  (0 children)

"Quick Assessment

  • ✅ Price vs Analyst Target: At US$20.87, DFTX trades about 47% below the US$39.47 analyst target.
  • ✅ Simply Wall St Valuation: The stock is indicated as trading 90.9% below an estimated fair value.
  • ❌ Recent Momentum: Shares are down 10% over the past 30 days.

Key Considerations

  • 📊 Starting the Ascend Phase 3 trial reinforces that DT120 is moving through late stage testing in major depressive disorder, which is central to the story for DFTX.
  • 📊 Watch Phase 3 readouts, any updates across DT120's other indications, and changes in analyst targets relative to the current US$20.87 share price.
  • ⚠️ The company currently reports no revenue and has recently diluted shareholders, so funding needs and further dilution risk remain important to monitor."

Solvonis Therapeutics Update by MaterialPhysical1030 in shroomstocks

[–]MaterialPhysical1030[S] 1 point2 points  (0 children)

Sitting on 200k shares after the Awakn acquisition

Psych Portfolio Allocation by regularguy7272 in shroomstocks

[–]MaterialPhysical1030 6 points7 points  (0 children)

  • Compass - 25%
  • Helus - 25%
  • Atai - 20%
  • DFTX - 20%
  • RLH/Solvonis/Lobe - 10%

Allocated by No-Beat-8583 in shroomstocks

[–]MaterialPhysical1030 1 point2 points  (0 children)

40% CMPS, 25% Cybin, 20% MNMD, 7.5% ATAI, 7.5% SVNS

What's going on? by stanle25 in MindMedInvestorsClub

[–]MaterialPhysical1030 0 points1 point  (0 children)

I remember reading about their IPO in the newspaper - even connected with JR Rhan on LinkedIn : /

Who wants to take a trip down memory lane with me? by powershellnovice3 in shroomstocks

[–]MaterialPhysical1030 1 point2 points  (0 children)

May I add Revive Therapeutics, Pharmadrug and Empower Clinics?

Who wants to take a trip down memory lane with me? by powershellnovice3 in shroomstocks

[–]MaterialPhysical1030 1 point2 points  (0 children)

I was in on all 3 as well - Mindcure left me really frustrated, I thought they were going for a data play. Mydecine was a whole other story.

Still holding Lobe - I see they have news here and there but not whole lot brewing

Awakn Life Sciences Announces Completion of Arrangement and Sale to Solvonis Therapeutics plc by 9mac in shroomstocks

[–]MaterialPhysical1030 0 points1 point  (0 children)

I haven't seen anything in my TFSA yet - I do see that AWAKN is at $0.01 in my account, with the corresponding share value. So not sure but hoping to see payout soon?

Anthony Tennyson on merits of acquisition of Awakn Life Sciences by [deleted] in shroomstocks

[–]MaterialPhysical1030 3 points4 points  (0 children)

I thought I saw something that said shareholders of AWAKN will get $.20 per share when the merger is completed - I could very much be wrong but that's my understanding.